Mark Chin's Insider Trades & SAST Disclosures
Mark Chin's most recent trade in Disc Medicine Inc was a trade of 10,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark Chin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Disc Medicine Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Harpoon Therapeutics Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 1,072 | 12,801 (0%) | 0% | 0 | Common Stock | |
| Harpoon Therapeutics Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2023 | 18,656 | 36,941 (0%) | 0% | 0 | Common Stock | |
| Harpoon Therapeutics Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2023 | 23,000 | 23,000 | - | - | Director Stock Option (Right to Buy) | |
| Iterum Therapeutics Plc | Mark Chin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 15,853 | 0 | - | - | Restricted Share Units | |
| Iterum Therapeutics Plc | Mark Chin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2023 | 15,853 | 18,306 (0%) | 0% | 0 | Ordinary Shares | |
| Disc Medicine Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 7,136 | 7,136 | - | - | Stock Option (Right to Buy) | |
| Harpoon Therapeutics Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 18,285 | 18,285 (0%) | 0% | 0 | Common Stock | |
| Disc Medicine Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2022 | 7,000 | 7,000 | - | - | Stock Option (Right to Buy) | |
| Iterum Therapeutics Plc | Mark Chin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2022 | 36,798 | 36,798 (0%) | 0% | - | Ordinary Shares | |
| Iterum Therapeutics Plc | Mark Chin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2022 | 36,798 | 0 | - | - | Restricted Share Units | |
| Harpoon Therapeutics Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 32,142 | 32,142 | - | - | Director Stock Option (Right to Buy) | |
| Harpoon Therapeutics Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 10,167 | 10,167 | - | - | Director Stock Option (Right to Buy) | |
| Iterum Therapeutics Plc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 237,795 | 237,795 | - | - | Restricted Share Units | |
| Pyxis Oncology Inc | Mark Chin | Former Director | Sale of securities on an exchange or to another person at price $ 3.05 per share. | 21 Apr 2022 | 1,745,761 | 0 | - | 3.0 | 5,324,571 | Common Stock |
| Pyxis Oncology Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 66,831 | 66,831 | - | 0 | Common Stock | |
| Pyxis Oncology Inc | Mark Chin | Director | 13 Oct 2021 | 9,114,109 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Pyxis Oncology Inc | Mark Chin | Director | 13 Oct 2021 | 1,433,261 | 1,433,261 | - | - | Common Stock | ||
| Pyxis Oncology Inc | Mark Chin | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 13 Oct 2021 | 312,500 | 1,745,761 | - | 16 | 5,000,000 | Common Stock |
| Pyxis Oncology Inc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2021 | 42,191 | 42,191 | - | - | Stock Option (Right to buy) | |
| Iterum Therapeutics Plc | Mark Chin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 36,798 | 36,798 | - | - | Restricted Stock Units | |
| Iterum Therapeutics Plc | Mark Chin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2020 | 5,703 | 0 | - | - | Restricted Stock Units | |
| Iterum Therapeutics Plc | Mark Chin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2020 | 5,703 | 11,857 (0%) | 0% | - | Ordinary Shares | |
| Harpoon Therapeutics Inc | Mark Chin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 10,167 | 10,167 | - | - | Director Stock Option (Right to Buy) | |
| Harpoon Therapeutics Inc | Mark Chin | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 3,017 | 3,017 | - | - | Director Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges